Targeting specific cancer genes to improve treatment for leukemia
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors
This study is looking at how certain genes that can cause cancer affect the treatment of acute myeloid leukemia and related blood disorders, and it aims to find better ways to help patients with these conditions by using special drugs that target the cancer cells' weaknesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10809630 on NIH RePORTER |
What this research studies
This research investigates how certain cancer-causing genes, known as oncogenic tyrosine kinases, affect the treatment of acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs). The study focuses on how these genes can make cancer cells resistant to treatment by altering DNA repair mechanisms. By using targeted inhibitors and PARP inhibitors, the research aims to exploit the weaknesses in the cancer cells' ability to repair DNA damage, potentially leading to more effective therapies. Patients with specific genetic mutations may be treated with these inhibitors to enhance their response to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with FLT3(ITD)-positive acute myeloid leukemia or JAK2(V617F)-positive myeloproliferative neoplasms.
Not a fit: Patients without these specific genetic mutations or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with certain types of leukemia, improving their chances of remission.
How similar studies have performed: Previous research has shown promise in using targeted therapies and PARP inhibitors in similar contexts, indicating a potential for success in this approach.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Skorski, Tomasz — Temple Univ of the Commonwealth
- Study coordinator: Skorski, Tomasz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.